NEW YORK, Oct. 16, 2015 /PRNewswire/ -- Levi & Korsinsky, LLP announces that it has commenced an investigation of Zafgen, Inc. ("Zafgen" or the "Company") (Nasdaq: ZFGN) concerning possible violations of federal securities laws by certain officers and directors.
On October 14, 2015, Zafgen issued a statement acknowledging the death of a patient in its ongoing Phase 3 study of Beloranib in Prader-Will Syndrome. In reaction to this announcement, Zafgen shares fell to a close of $21.02 per share on October 15, 2015, down from the previous week's high of $35.18 on October 7, 2015. To obtain additional information about our investigation, please go to: http://zlk.9nl.com/zafgen-zfgn or contact Joseph E. Levi, Esq. at: [email protected], (212) 363-7500, or toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C recognized for its excellence in representing shareholders of various kinds. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
Logo - http://photos.prnewswire.com/prnh/20120409/MM84375LOGO
SOURCE Levi & Korsinsky, LLP
Share this article